Opinion

Claudia Rubin and Tom Jaggs explore the implications of the High Court ruling against Novartis and Bayer for pharma. High Court ruling against Novartis and...

“The challenge now is for the NHS to respond to this changing landscape and to focus on preventing as well as treating the conditions...

Have business analytics been pushed to the background? Business information upgraded, smart CRM datasets, the Predictive Analytics silver bullet and other fairy tales.

James Burt, Executive Vice President EMENA, Accord Healthcare, asks whether Brexit will in fact present an opportunity for positive change in pharma and healthcare.

Could changes at the top mean fresh opportunities for tech innovation? Read this in the August issue of Pf Magazine.  For some time it has been...

Read this in the August issue of Pf Magazine.  Community pharmacy has a clear role in promoting and supporting the public’s health. There’s an accessible...

Blockchain is one of the most talked about technologies at the moment and boasts huge potential to transform how we deliver healthcare and revolutionise...

What are the implications for the movement of medicines from and into the UK, post-brexit? Mark Quick, executive vice president of corporate development at Recipharm, comments on the current situation and the potential implications of the UK exiting the European Union (EU).

These 5 things are what pharmaceutical companies should be focusing on to maximise their growth in the UK.

From birthday teas to big policy, blood donor drives to special 10p coins, the 70th anniversary of the creation of the NHS is getting...